ESR1 and breast carcinoma: The risk-of-recurrence calculated from follow-up data from METABRIC (Rueda et al., 2019), based on FOXM1 gene expression in the primary tumor, showed that the risk of relapse is increased in ER+ breast cancer compared with ER− breast cancer (Figure S6G).